Neonatal catecholamine levels and neurodevelopmental outcome: a cohort study

D J Evans, R J MacGregor, H G Dean, M I Levene

Abstract

Aims—To determine whether neonatal plasma catecholamine concentrations can be used to predict (a) death plus disability and (b) motor and cognitive impairment at 5 years of age.

Methods—A cohort comprised 136 preterm infants from two randomised controlled trials of neonatal sedation (1989–1992). Adrenaline (epinephrine) and noradrenaline (norepinephrine) were measured at baseline (first day) and 24 hours later. Intelligence and motor ability were assessed at 5–6 years.

Results—Infants who died or sustained disability had significantly higher plasma noradrenaline levels on the second day of life. Noradrenaline levels above 9.0 nmol/l were most predictive of death (likelihood ratio 3.27; 95% confidence interval 1.48 to 7.23) and death plus disability (likelihood ratio 3.55; 95% confidence interval 1.77 to 7.10). There was no correlation between neonatal catecholamine levels and cognitive or motor impairment at 5–6 years.

Conclusions—Elevated noradrenaline levels are associated with adverse outcome in preterm infants; however, the power to predict death or disability is limited and they are not predictive of later motor or cognitive impairment.

(Keywords: adrenaline; noradrenaline; catecholamines; intelligence; motor function; predictive ability)

Preterm infants undergoing intensive care are capable of mounting a hormonal response to the stress of their illness and treatment, manifested by high catecholamine concentrations. In infants suffering from respiratory distress syndrome, adrenaline (epinephrine) and noradrenaline (norepinephrine) concentrations have been found to correlate with measures of illness severity. Extreme baseline catecholamine concentrations and a reduced noradrenaline response to opiate sedation are associated with subsequent mortality. There are no data on the usefulness of catecholamine levels for predicting disability in addition to mortality. It is also not known whether there is a correlation between neonatal catecholamine concentrations and cognitive or motor development in childhood.

Survivors of preterm birth are at risk of developing neurodevelopmental and, in particular, motor impairment. If catecholamines correlate with disease severity, they may be expected to correlate with scores of motor, and possibly cognitive, impairment. A study was therefore undertaken to examine the following questions. Are elevated neonatal catecholamine levels associated with death and disability, and, if so, what is their predictive ability? Do neonatal catecholamine levels correlate with measures of motor and cognitive impairment in childhood?
Results

A total of 136 infants were recruited into the two randomised controlled trials, 95 of whom survived to 5–6 years of age. The characteristics of these infants has been previously described. Of the 95 surviving children, 87 (92%) had WPPSI-R and Movement ABC assessments. Of the eight children who were not seen, three could not be traced, for two of them permission to be assessed was refused, for two no reply was received to three letters, they lived outside Leeds, and they were not on the phone, and one child came from a travelling family. Fifteen of the children assessed were disabled. Four of these were unable to undergo the WPPSI-R or Movement ABC assessments because of severe disability. One child with quadriplegic cerebral palsy was only able to perform the verbal component of the WPPSI-R. Of the 11 disabled children able to complete fully the assessments, eight had cerebral palsy (two quadriplegia, four diplegia, two hemiplegia), one had severe learning difficulties, one had septo-optic dysplasia with learning difficulties, and one had Dubowitz syndrome and learning difficulties. All the children seen were included in the analyses. The children who could not be scored on IQ and motor assessments were given a nominal score of 30 for the WPPSI-R and the maximum score of 40 for the Movement ABC.

Complete neonatal catecholamine data were available for 68 (78%) of the surviving assessed children and 23 (56%) of the infants who died. Table 1 gives the gestational age and birth weights of the 128 infants with outcome data (41 deaths and 87 follow up) and the 91 infants with outcome data plus complete catecholamine data.

Table 2 gives the median plasma adrenaline and noradrenaline concentrations at baseline and baseline + 24 hours and the change in concentration over 24 hours. Generally, catecholamine concentrations were higher in infants who subsequently died or were found to have disability. The greatest statistical differences in concentrations were seen with noradrenaline at baseline + 24 hours. Noradrenaline levels were highest in infants who died (p = 0.0002) and remained high in the death plus disability group (p = 0.003; table 2). Catecholamine concentrations decreased over the 24 hour neonatal study period except noradrenaline levels in those infants who died. In these infants, the noradrenaline levels actually rose, presumably reflecting a greater severity of disease. In the subgroup analysis of neonates receiving morphine, there was evidence that a reduced noradrenaline response to opiate
Predictive power of noradrenaline levels

Figure 2 Relative (receiver) operating characteristic curves for different concentrations of noradrenaline at baseline + 24 hours, in the prediction of (A) death and (B) death plus disability. Concentrations indicated next to data points are in units of nmol/l.

Figure 3 Scatter plots of baseline adrenaline and noradrenaline concentrations against IQ (Wechsler preschool and primary scale of intelligence (WPPSI-R)) scores and Movement assessment battery for children (Movement ABC) scores in the 68 surviving children. $r_s = -0.07$ (p > 0.20) and $r_s = 0.04$ (p > 0.20), respectively.

Discussion
This study confirms previously published data suggesting an association between elevated neonatal catecholamine levels and mortality. It also suggests that both infants who die and those who develop disability have elevated neonatal catecholamine levels. This study goes further in critically examining the relation between high catecholamines and both death and disability from a viewpoint of clinical utility. A noradrenaline concentration above 9.0 nmol/l is predictive of both death and death plus disability (fig 2). Despite the statistically significant likelihood ratios, however, the magnitudes of the ratios are low—that is, the odds after the test are only three times those before the test—and the lower limits of the 95% CI are close to unity. In comparison, the likelihood ratio of a major ultrasound abnormality in the prediction of death or disability in a similar preterm population is 3.9 (95% CI 2.5 to 6.1). A larger study would allow more precision surrounding the estimate of the likelihood ratio. If neonatal catecholamines were to perform at least as well as ultrasound—that is, taking a ratio of 2.5 as the lowest acceptable likelihood ratio—a sample size of 770 infants would be required. Thus it is unlikely that catecholamine concentrations will ever be shown to be clinically useful in the prediction of death or disability.

Barker and Rutter suggest that a reduced noradrenaline response to opiate sedation—that is, a persistently high noradrenaline level despite six hours of sedation—was associated with increased mortality. This was confirmed in this study, although there was no evidence that a reduced noradrenaline response to sedation over 24 hours was associated with disability (fig 1).

The most severely ill infants are more likely to receive inotropes, the metabolites of which may raise blood noradrenaline concentrations. It is therefore possible that changes in adrenaline and noradrenaline are masked or altered by inotropic support, such as dopamine treatment. This appears not to be the case, however, because a review of the treatment charts shows that only two infants in the death and disability group and four in the intact survival group received dopamine treatment or adrenaline for resuscitation.

Survivors of preterm birth are at risk of developing neurodevelopmental and, in particular, motor impairment. If catecholamines correlate with disease severity, they may be expected to correlate with scores of motor, and possibly cognitive, impairment. Neither adrenaline nor noradrenaline concentrations were correlated with either Movement ABC scores or IQ. It is unlikely that either attrition or the assessments having poor discriminatory power are reasons for a potential correlation being missed by this study. Over 90% of the surviving children have been traced and assessed as part of this study, and one experienced neurodevelopmental paediatrician assessed all the children. Both assessments produced a wide range of scores. Some 20% of the surviving cohort assessed had significant disability, as previously defined. Although this is somewhat higher than many reports, this reflects the cohort’s high risk nature because of the prerequisite for mechanical ventilation.
Although there is some evidence that high catecholamine levels in the neonatal period are associated with death and disability, there is no evidence to suggest that they have any prognostic significance in terms of motor impairment or cognitive ability. It is still unclear whether high catecholamine concentrations are, in themselves, detrimental or whether they represent an adaptive response. There is a theoretical concern that measures to reduce catecholamines, such as opiate sedation, may blunt this adaptive response and lead to higher mortality and morbidity in surviving infants. From clinical studies, however, the reductions in catecholamine levels associated with morphine treatment and antenatal corticosteroids do not appear to be associated with a detrimental effect.

In summary, this study describes an association between elevated catecholamine levels and adverse outcome in preterm infants; however, the power to predict death or disability is limited. Neonatal catecholamine concentrations do not correlate with measures of motor or cognitive impairment in surviving children.

This work was supported by funding from Action Research. We are grateful to Mrs Jenny Wild for assistance with tracing the children.

Neonatal catecholamine levels and neurodevelopmental outcome: a cohort study

D J Evans, R J MacGregor, H G Dean and M I Levene

Arch Dis Child Fetal Neonatal Ed 2001 84: F49-F52
doi: 10.1136/fn.84.1.F49

Updated information and services can be found at:
http://fn.bmj.com/content/84/1/F49

These include:

References

This article cites 12 articles, 1 of which you can access for free at:
http://fn.bmj.com/content/84/1/F49#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

- Drugs: CNS (not psychiatric) (191)
- Child health (1515)
- Infant health (857)
- Memory disorders (psychiatry) (16)
- Neonatal health (928)
- Other anaesthesia (61)
- Clinical trials (epidemiology) (252)
- Epidemiologic studies (929)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/